Bio-IT World 2026: AI in Oncology Takes Center Stage
The Bio-IT World Conference & Expo 2026 will focus on AI applications in life sciences and includes a dedicated AI for Oncology track. The conference will be held in Boston from May 19-21, 2026, in a hybrid format.
Intelligence Snapshot
Executive Summary
Bio-IT World Conference & Expo 2026 will focus on AI applications in life sciences.
Key Insights
- The event includes a dedicated AI for Oncology track.
- No specific oncology drug data or clinical trial results are expected to be presented.
- The conference will be held in Boston from May 19-21, 2026, in a hybrid format.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Executive Scorecard
Heuristic scores · directional, not investment adviceContents8 sections
Key Takeaways
- Bio-IT World Conference & Expo 2026 will focus on AI applications in life sciences.
- The event includes a dedicated AI for Oncology track.
- No specific oncology drug data or clinical trial results are expected to be presented.
- The conference will be held in Boston from May 19-21, 2026, in a hybrid format.
The Bio-IT World Conference & Expo, a leading event for bioinformatics, IT, and data science professionals in the life sciences, will take place in Boston from May 19-21, 2026. The conference will explore the latest advancements in AI, data science, and other technologies impacting drug discovery and development. A dedicated "AI for Oncology" track will be featured.
The 25th Annual Bio-IT World Conference & Expo aims to connect biopharma, IT, and research professionals to discuss innovations in data science and AI. The hybrid event, held at the Omni Boston Hotel at the Seaport, will offer both in-person and virtual attendance options.
Conference Overview
The Bio-IT World Conference & Expo 2026 is scheduled for May 19–21, 2026, in Boston, focusing on life sciences, healthcare, biotech, informatics, precision medicine, AI, data analytics, and R&D workflows. The conference will be held in a hybrid format, offering both in-person and virtual attendance.
Key focus areas include:
- AI applications in drug development
- Data science innovations in pharma R&D workflows
- Quantum computing for drug discovery
IntelligenceRegulatory Impact
FDA are the agencies to watch. Regulatory relevance reads medium for oncology. Teams should track submission types, designations, and guidance shifts that could move approval timelines.
AI for Oncology Track
The conference will feature a dedicated AI for Oncology track. This track will cover the deployment of AI for cancer therapies. However, available sources do not list specific oncology drugs, International Nonproprietary Names (INN), clinical trial National Clinical Trial (NCT) numbers, or company drug pipelines.
IntelligenceCompetitive Intelligence
Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.
Related Sessions
In addition to the AI for Oncology track, the conference will include related sessions such as:
- A plenary session on federated learning for structural biology data sharing, featuring speakers from Columbia University, Eli Lilly, Apheris, Psivant Therapeutics, and Bayer.
- The Bio-IT World FAIR Data Hackathon, which will include projects such as "Visible Neural Networks for Cancer Drug Response (CellMap-VNN)" and "Drug Repurposing via Disease Similarity and Biomarker Networks."
- An Innovation Showcase featuring emerging AI companies for the life sciences, such as MadeAI and Redouble AI.
IntelligenceMarket Signals
Commercial pull is medium and investment relevance low. Expect implications for oncology pricing, access, and launch sequencing.
No Oncology Drugs Data Found
Current sources lack details on specific oncology drugs (INN), clinical trials (NCT), or company presentations with drug data. While Inductive Bio won a prediction competition, no specific oncology drug disclosures for 2026 have been announced.
Frequently Asked Questions
-
What is the Bio-IT World Conference & Expo 2026 about?
It is a conference focusing on the applications of AI and data science in life sciences, drug discovery, and healthcare.
-
When and where will the conference take place?
The conference will be held from May 19-21, 2026, in Boston, MA, at the Omni Boston Hotel at the Seaport.
-
Is there a specific focus on oncology?
Yes, there is a dedicated "AI for Oncology" track at the conference.
-
Will there be presentations on specific oncology drugs or clinical trial data?
Based on currently available information, no specific oncology drug data or clinical trial results are expected to be presented.
-
How can I attend the conference?
The conference is a hybrid event, offering both in-person and virtual attendance options. Advance registration ends April 10, 2026.
References
- Rozie Synopsis: 10 Healthcare Conferences in 2026 Worth Adding to Your Calendar
- Intuition Labs: Conferences
- BioSpace Press Release: Impact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026
- HealthTech.com
- Maat Pharma: Bio International Convention 2026
- ALMCORP: AI Conferences in May 2026
- Simons Foundation: National Institute for Theory and Mathematics in Biology Annual Meeting 2026
Related coverage
Ask AI About oncology
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Track oncology news weekly
FDA oncology news and regulatory updates, every Monday.
- Evidence strength
- 71/100
- Last verified
- Jun 15, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Moderate source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
Industry Reports & Whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…